Esperion Therapeutics ESPR Convertible Debt (Non-Current)
Convertible Debt (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's convertible debt (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's convertible debt (non-current)?
- Esperion Therapeutics (ESPR) reported convertible debt (non-current) of $97.39M in Q1 2026.
- How has Esperion Therapeutics's convertible debt (non-current) changed year-over-year?
- Esperion Therapeutics's convertible debt (non-current) increased by 0.5% year-over-year, from $96.87M to $97.39M.
- What is the long-term trend for Esperion Therapeutics's convertible debt (non-current)?
- Over 5 years (2020 to 2025), Esperion Therapeutics's convertible debt (non-current) has grown at a -11.5% compound annual growth rate (CAGR), from $179.37M to $97.26M.
- What does convertible debt (non-current) mean?
- This represents the principal amount of debt that is convertible into equity and matures beyond the one-year horizon. It provides long-term capital to support business operations while offering a potential path to equity conversion. Investors analyze this to evaluate the company's long-term capital structure and potential future dilution.